Prognostic Significance of CD200 Protein Expression and its Correlation with COX-2 in Cutaneous Melanoma
Description
Supplementary Figure 1. Expression of CD200 and COX-2 in melanoma tissue. Immunohistochemical staining for (A) CD200 (X 100) and (B) COX-2 (X 40) in melanoma tissue. Paraffin-embedded sections were immunostained with anti-CD200 (R&D systems, Minneapolis, MN, USA; 1:5000) and anti-COX-2 (Neomarkers, CA, USA; 1:50). Double immunofluorescence staining in melanoma tissue of (C) melan-A and CD200 (melan-A, red; CD200, green), (D) melan-A and COX-2 (melan A, red; COX-2, green), and (E) CD200 and COX-2 (CD200, green; COX-2, red). Double-positive cells are indicated by the yellow signals. (F) Correlation between CD200 and COX-2 protein expression in cutaneous melanoma. Supplementary Figure 2. Progression-free survivals depending on (A) CD200 (B) COX-2 expression in melanoma patients. COX-2, cyclooxygenase-2 Supplementary Figure 3. Effects of COX-2 inhibitor on the expression of CD200 in melanoma cell line. (A, B) Western blotting analysis to evaluate the effect of COX-2 inhibitor on the level of CD200 in Human BRAFV600E A375 melanoma cell. A375 cells were treated with the selective COX-2 inhibitor, celecoxib at different doses. CD200 was downregulated by celecoxib at dose from 60 μM. *p < 0.05, **p < 0.01.